Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas

Next Previous
Search
Trial Profile

Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SL 279252 (Primary)
  • Indications Adenocarcinoma; Anal cancer; B-cell lymphoma; Cervical cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Skin cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Shattuck Labs

    • Most Recent Events

    • 20 Nov 2023 Planned End Date changed from 31 Oct 2023 to 31 Dec 2023.
    • 20 Nov 2023 Planned primary completion date changed from 30 Jul 2023 to 31 Dec 2023.
    • 23 Feb 2023 Status changed from recruiting to discontinued as the company did not observe an overall response rate necessary to justify continued development in a very difficult PD-1 relapsed/refractory patient population

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top